Niagen Bioscience (NAGE) Competitors

$3.66 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.71 +0.05 (+1.34%)

As of 05/22/2026 07:40 PM Eastern

NAGE vs. HROW, CALT, MPLT, AVLN, and PURR

Should you buy Niagen Bioscience stock or one of its competitors? MarketBeat compares Niagen Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Niagen Bioscience include Harrow (HROW), Calliditas Therapeutics AB (publ) (CALT), Maplight Therapeutics (MPLT), Avalyn Pharma (AVLN), and Hyperliquid Strategies (PURR). These companies are all part of the "pharmaceutical products" industry.

How does Niagen Bioscience compare to Harrow?

Niagen Bioscience (NASDAQ:NAGE) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Niagen Bioscience has higher earnings, but lower revenue than Harrow. Harrow is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43
Harrow	$272.30M	4.52	-$5.14M	-$0.41	N/A

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Niagen Bioscience currently has a consensus target price of $14.67, indicating a potential upside of 300.73%. Harrow has a consensus target price of $69.43, indicating a potential upside of 110.39%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Niagen Bioscience is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Niagen Bioscience has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Harrow has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

In the previous week, Harrow had 10 more articles in the media than Niagen Bioscience. MarketBeat recorded 12 mentions for Harrow and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.00 beat Harrow's score of 0.70 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has a net margin of 14.29% compared to Harrow's net margin of -5.57%. Niagen Bioscience's return on equity of 22.68% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Harrow	-5.57%	19.59%	2.26%

Summary

Niagen Bioscience beats Harrow on 10 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Calliditas Therapeutics AB (publ)?

Niagen Bioscience (NASDAQ:NAGE) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Niagen Bioscience has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Niagen Bioscience currently has a consensus price target of $14.67, indicating a potential upside of 300.73%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Niagen Bioscience is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Niagen Bioscience had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Niagen Bioscience and 0 mentions for Calliditas Therapeutics AB (publ). Niagen Bioscience's average media sentiment score of 1.00 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Niagen Bioscience	Positive
Calliditas Therapeutics AB (publ)	Neutral

Niagen Bioscience has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Niagen Bioscience has a net margin of 14.29% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Niagen Bioscience's return on equity of 22.68% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Summary

Niagen Bioscience beats Calliditas Therapeutics AB (publ) on 15 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Maplight Therapeutics had 6 more articles in the media than Niagen Bioscience. MarketBeat recorded 8 mentions for Maplight Therapeutics and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.00 beat Maplight Therapeutics' score of -0.32 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.4% of Niagen Bioscience shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Niagen Bioscience has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43

Niagen Bioscience has a net margin of 14.29% compared to Maplight Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Niagen Bioscience	14.29%	22.68%	16.23%

Maplight Therapeutics presently has a consensus price target of $35.50, suggesting a potential upside of 23.48%. Niagen Bioscience has a consensus price target of $14.67, suggesting a potential upside of 300.73%. Given Niagen Bioscience's higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Niagen Bioscience beats Maplight Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Niagen Bioscience compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Niagen Bioscience has higher revenue and earnings than Avalyn Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43

Avalyn Pharma presently has a consensus target price of $66.00, indicating a potential upside of 128.85%. Niagen Bioscience has a consensus target price of $14.67, indicating a potential upside of 300.73%. Given Niagen Bioscience's higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Niagen Bioscience has a net margin of 14.29% compared to Avalyn Pharma's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Niagen Bioscience	14.29%	22.68%	16.23%

15.4% of Niagen Bioscience shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Avalyn Pharma had 2 more articles in the media than Niagen Bioscience. MarketBeat recorded 4 mentions for Avalyn Pharma and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.00 beat Avalyn Pharma's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Niagen Bioscience beats Avalyn Pharma on 9 of the 11 factors compared between the two stocks.

How does Niagen Bioscience compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Hyperliquid Strategies currently has a consensus price target of $9.25, suggesting a potential upside of 20.60%. Niagen Bioscience has a consensus price target of $14.67, suggesting a potential upside of 300.73%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Hyperliquid Strategies had 7 more articles in the media than Niagen Bioscience. MarketBeat recorded 9 mentions for Hyperliquid Strategies and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.00 beat Hyperliquid Strategies' score of 0.57 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Niagen Bioscience has higher revenue and earnings than Hyperliquid Strategies. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,032.54	-$16.01M	-$7.37	N/A
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43

Hyperliquid Strategies has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market.

Niagen Bioscience has a net margin of 14.29% compared to Hyperliquid Strategies' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Niagen Bioscience	14.29%	22.68%	16.23%

Summary

Niagen Bioscience beats Hyperliquid Strategies on 13 of the 15 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAGE vs. The Competition

Export

Metric	Niagen Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$291.50M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	17.43	18.74	21.21	25.65
Price / Sales	2.25	323.98	554.38	86.31
Price / Cash	18.05	125.17	43.49	56.67
Price / Book	3.55	7.09	10.37	7.14
Net Income	$17.38M	$24.45M	$3.57B	$335.98M
7 Day Performance	N/A	6.38%	6.40%	4.15%
1 Month Performance	-25.76%	2.43%	3.53%	2.54%
1 Year Performance	-62.96%	62.98%	34.04%	35.06%

Niagen Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAGE Niagen Bioscience	4.0665 of 5 stars	$3.66 flat	$14.67 +300.7%	-63.0%	$291.50M	$129.42M	17.43	120	Positive News Gap Up
HROW Harrow	4.5143 of 5 stars	$31.97 +3.6%	$69.43 +117.2%	+27.4%	$1.19B	$272.30M	N/A	180
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
MPLT Maplight Therapeutics	2.8858 of 5 stars	$27.59 -0.8%	$35.50 +28.7%	N/A	$1.18B	N/A	N/A	109
AVLN Avalyn Pharma	N/A	$27.85 -0.6%	N/A	N/A	$1.16B	N/A	N/A	51	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAGE) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Competitors

NAGE vs. HROW, CALT, MPLT, AVLN, and PURR

How does Niagen Bioscience compare to Harrow?

Summary

How does Niagen Bioscience compare to Calliditas Therapeutics AB (publ)?

Summary

How does Niagen Bioscience compare to Maplight Therapeutics?

Summary

How does Niagen Bioscience compare to Avalyn Pharma?

Summary

How does Niagen Bioscience compare to Hyperliquid Strategies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Competitors

NAGE vs. HROW, CALT, MPLT, AVLN, and PURR

How does Niagen Bioscience compare to Harrow?

Which has higher valuation & earnings, NAGE or HROW?

Do insiders & institutionals believe in NAGE or HROW?

Do analysts rate NAGE or HROW?

Which has more volatility & risk, NAGE or HROW?

Does the media prefer NAGE or HROW?

Is NAGE or HROW more profitable?

Summary

How does Niagen Bioscience compare to Calliditas Therapeutics AB (publ)?

Which has more volatility & risk, NAGE or CALT?

Do institutionals & insiders believe in NAGE or CALT?

Do analysts prefer NAGE or CALT?

Does the media prefer NAGE or CALT?

Which has higher valuation and earnings, NAGE or CALT?

Is NAGE or CALT more profitable?

Summary

How does Niagen Bioscience compare to Maplight Therapeutics?

Does the media prefer MPLT or NAGE?

Do institutionals and insiders hold more shares of MPLT or NAGE?

Which has stronger earnings & valuation, MPLT or NAGE?

Is MPLT or NAGE more profitable?

Do analysts recommend MPLT or NAGE?

Summary

How does Niagen Bioscience compare to Avalyn Pharma?

Which has preferable valuation and earnings, AVLN or NAGE?

Do analysts prefer AVLN or NAGE?

Is AVLN or NAGE more profitable?

Do institutionals and insiders believe in AVLN or NAGE?

Does the media refer more to AVLN or NAGE?

Summary

How does Niagen Bioscience compare to Hyperliquid Strategies?

Do analysts recommend PURR or NAGE?

Does the media favor PURR or NAGE?

Do institutionals & insiders hold more shares of PURR or NAGE?

Which has preferable valuation and earnings, PURR or NAGE?

Which has more risk and volatility, PURR or NAGE?

Is PURR or NAGE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools